CIK 1977548
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 8 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARGX | Argenx SE | Health Care | 40.10% |
| 2 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Health Care | 38.30% |
| 3 | RVMD | Revolution Medicines, Inc. | Health Care | 9.16% |
| 4 | IRON | Disc Medicine, Inc. | Health Care | 6.58% |
| 5 | CYTK | CYTOKINETICS INC | Health Care | 4.26% |
| 6 | SEPN | Septerna, Inc. | Health Care | 0.86% |
| 7 | CRNX | Crinetics Pharmaceuticals, Inc. | Health Care | 0.52% |
| 8 | TRVI | Trevi Therapeutics, Inc. | Health Care | 0.21% |
8/8 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 59.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/8 names) · unclassified 100.0%: ARGX, RYTM, RVMD, IRON, CYTK, SEPN, CRNX, TRVI. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARGXARGENX SE | 153,000 | $112M | 40.1% | ADD 8% |
| 2 | RYTMRHYTHM PHARMACEUTICALS INC | 1,227,200 | $107M | 38.3% | ADD 24% |
| 3 | RVMDREVOLUTION MEDICINES INC | 262,539 | $26M | 9.2% | TRIM −29% |
| 4 | IRONDISC MEDICINE INC | 286,661 | $18M | 6.6% | TRIM −37% |
| 5 | CYTKCYTOKINETICS INC | 180,000 | $12M | 4.3% | ADD 8% |
| 6 | SEPNSEPTERNA INC | 100,300 | $2M | 0.9% | NEW |
| 7 | CRNXCRINETICS PHARMACEUTICALS IN | 40,230 | $1M | 0.5% | NEW |
| 8 | TRVITREVI THERAPEUTICS INC | 50,000 | $596,500 | 0.2% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARGXARGENX SE | 93K | 115K | 150K | 150K | 142K | 153K | $112M |
| RYTMRHYTHM PHARMACEUTICALS INC | 728K | 907K | 1.1M | 764K | 992K | 1.2M | $107M |
| RVMDREVOLUTION MEDICINES INC | 210K | 392K | 280K | 492K | 370K | 263K | $26M |
| IRONDISC MEDICINE INC | 185K | 243K | 265K | 430K | 453K | 287K | $18M |
| CYTKCYTOKINETICS INC | 20K | — | — | 38K | 167K | 180K | $12M |
| SEPNSEPTERNA INC | — | 825K | 586K | 283K | — | 100K | $2M |
| CRNXCRINETICS PHARMACEUTICALS IN | — | — | — | 260K | — | 40K | $1M |
| TRVITREVI THERAPEUTICS INC | 1.1M | — | — | — | — | 50K | $596,500 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
